Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
rein. Alseres is providing the information in this pressrelease as of...Contact: Sharon Correia - 508-497-2360 ext 224 ... Alseres Pharmaceuticals Inc. ... scorreia@alseres.com/A...
Date:3/31/2008
rein. Alseres is providing the information in this press
release as of this date and assumes no obligations to update the
information in this press release.
Contact: Sharon Correia - 508-497-2360 ext 224
Alseres Pharmaceuticals, Inc.
scorreia@alseres.com
'/>"/>SOURCE Alseres Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
Alseres Pharmaceuticals, Inc. Raises $5 Million2.
Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference3.
Barr Pharmaceuticals, Inc. Executive Bios4.
Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation5.
Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic6.
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board7.
Renhuang Pharmaceuticals, Inc. Retains CCG Elite8.
Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies9.
Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 200810.
NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers11.
Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR